Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FFNK6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $16,584.13 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. This firm fixed-price delivery order, issued on November 24, 2025, with an ultimate completion date of December 16, 2025, carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The award was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical and medical supply support to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with demonstrated performance across a diverse product portfolio spanning oncology treatments, immunosuppressants, biologics, vaccines, and specialty pharmaceuticals. The parent IDC, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 and an ultimate completion date of December 31, 2036, structured with a 30-month base period and three 30-month option periods. Through this contracting vehicle, the company supplies firm fixed-price delivery orders supporting recurring medical supply needs of military healthcare operations, positioning it as one of multiple regional prime vendor contractors within the broader PPV-G GEN V framework established to enhance pharmaceutical availability and cost efficiency across the Department of Defense medical system.
Quick answers
Who was awarded contract SPE2DR26FFNK6?
SPE2DR26FFNK6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 24, 2025.
How much is contract SPE2DR26FFNK6 worth?
The government has obligated $16,584 on SPE2DR26FFNK6.
Is contract SPE2DR26FFNK6 an order under another contract?
Yes. SPE2DR26FFNK6 is a delivery order under SPE2DR25D9249, an indefinite delivery contract.
Was contract SPE2DR26FFNK6 competed?
The extent of competition for SPE2DR26FFNK6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award